Hutchison China Meditech Share Chat (HCM)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Hutchison China Meditech	LSE:HCM	London	Ordinary Share	KYG4672N1016	ORD USD1

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+25.00p	+0.54%	4,675.00p	4,650.00p	4,700.00p	4,700.00p	4,650.00p	4,650.00p	5,475	14:00:17

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	178.6	-39.6	-31.8	-	2,840.07

Hutchison China Meditech Share Discussion Threads

Showing 1476 to 1499 of 1500 messages

Chat Pages: 60 59 58 57 56 55 54 53 52 51 50 49 Older

Date	Subject	Author	Discuss
23/4/2018 07:55	Thanks nerd, I may try to go, other commitments allowing.	mad foetus	Read Full Thread Reply
22/4/2018 09:32	hi mad, yes, going to the AGM, I think this will be my 6th or 7th year of attendance. The nice thing about the meeting is very few Private Shareholders attend, usually 3 or 4 at the most, so it gives you a good opportunity to talk to Board members and senior management directly. The CEO usually does a short presentation, based on the latest Co. one on the website, and is happy to answer non-material questions.	nerdofsteel	Read Full Thread Reply
22/4/2018 07:15	Also, any of you guys going to the AGM and/or if you have before would you recommend it? I'm just about free on Friday.	mad foetus	Read Full Thread Reply
22/4/2018 07:00	Thanks Lauders, and it does seem everything is on track. It is just frustrating how long these trials take a what a gestation period it is from concept to launch. Nature of the beast I know.	mad foetus	Read Full Thread Reply
22/4/2018 02:31	For those, like me, who like a record of things stated about HCM progress by other companies. Here are the relevant excerpts from the AZ report that NofS mentioned: 1 - “2017 was a pivotal year for Oncology, with important data readouts for osimertinib, olaparib, durvalumab and acalabrutinib. We made exciting progress with combinations: olaparib with other agents from our DNA damage response (DDR) portfolio, savolitinib with osimertinib, and AZD9150, our antisense oligonucleotide (ASO) signal transducer and activator of transcription 3 (STAT3) inhibitor, with durvalumab. In addition, we moved our cell death portfolio into the clinic. Translational science has been critical to these developments and is helping to ensure we treat patients who are most likely to benefit from our innovative approaches.” Susan Galbraith, Vice President, Head of IMED Oncology 2 - We progressed evaluation of savolitinib in collaboration with our Global Medicines Development (GMD) colleagues, by continued enrolment in a clinical study in c-MET-driven EGFR mutation positive non-small cell lung cancer (NSCLC), combining savolitinib with osimertinib in the TATTON trial and completing enrolment with gefitinib in a trial in China. Initiation of these studies was based on strong science highlighting the co-dependence on both c-MET and EGFR in some cancers and the potential for combining inhibitors targeting both of these receptor tyrosine kinases in a subset of patients with lung cancer. Clinical data were presented at the World Congress on Lung Cancer in Japan in 2017. A Phase III investment decision was made in 2016 for c-MET-driven papillary renal cell cancer (PRCC). Initiation of the Phase III trial in PRCC occurred in 2017, with enrolment ongoing. Savolitinib monotherapy continues to be explored in Phase I/II studies in other cancers, including stomach, kidney and lung, and in combination with durvalumab, a programmed death-ligand 1 (PD-L1) antibody, in kidney cancer. 3 - Savolitinib: a highly selective small molecule inhibitor of c-MET, partnered with Hutchison Pharma, is being evaluated in c-MET-driven cancers. It is currently in a confirmatory Phase III trial in PRCC, is also being evaluated in a Phase II trial in patients with a certain type of lung cancer.	lauders	Read Full Thread Reply
21/4/2018 09:32	Upside is hcm has more potential over medium and longer Term. It’s a real investment not a takeover punt.	dbadvn	Read Full Thread Reply
21/4/2018 08:31	true......unfortunately, and that has always put off American retail investors, who are looking for the next Juno or Pharmacyclics type deal by big Pharma with their patent cliffs...........	nerdofsteel	Read Full Thread Reply
20/4/2018 16:10	But.....HCM is bid proof	steeplejack	Read Full Thread Reply
19/4/2018 11:51	should pick-up in the US NASDAQ market as well, when it opens.	nimrod22	Read Full Thread Reply
19/4/2018 11:31	Rumours of Takada making an offer for Shire. Sector could get hot imo	mad foetus	Read Full Thread Reply
19/4/2018 11:01	Savolitinib gets plenty of coverage in AZN's annual review just published + Chi-Med detailed as partner hxxps://www.astrazeneca.com/content/dam/az/PDF/2017/IMED_Annual%20Review%202017_FINAL%20APPROVED.pdf#page=6	nerdofsteel	Read Full Thread Reply
19/4/2018 09:06	Looks like it has but it will be great to see the US reaction as well	mad foetus	Read Full Thread Reply
19/4/2018 07:48	Will be interesting to see if the news from AZN has any positive influence on HCM today.	lauders	Read Full Thread Reply
18/4/2018 07:18	thanks Lauders, I am in regular contact with Brad Loncars and alerted him to Chi-Med late last year. He is very bullish on Chinese Biotech.	nerdofsteel	Read Full Thread Reply
17/4/2018 03:08	While we wait for news here is a fairly recent piece on the Loncar Index from Xinhuanet: Http://www.xinhuanet.com/english/2018-03/17/c_137045318.htm World's first global index on China's biopharma industry launched in U.S. EDIT - Will the 6.8% growth expectations for China announced today and which beat forecasts be good for HCM? Hopefully a Chinese news related positive day here. Https://www.nytimes.com/2018/04/16/business/china-economy-trade-gap-united-states-grows.html	lauders	Read Full Thread Reply
16/4/2018 14:31	The trades at 1425 hrs & 1426 hrs are both buys	nimrod22	Read Full Thread Reply
13/4/2018 09:46	great find, thankyou nimrod, glad to see Brad Loncar has woken up to the huge potential in China and has even created his own Index	nerdofsteel	Read Full Thread Reply
12/4/2018 04:10	Good article in the FT re cancer treatment in China https://www.ft.com/content/30b5a944-3b57-11e8-b9f9-de94fa33a81e?emailId=5acde9bbf10cbb0004ce74d3&;segmentId=13b7e341-ed02-2b53-e8c0-d9cb59be8b3b	nimrod22	Read Full Thread Reply
11/4/2018 08:21	very wise DB.....NDA by CFDA coming shortly, let's hope the priority review process works as intended...	nerdofsteel	Read Full Thread Reply
10/4/2018 20:18	At this level i am buying for the first time in 4 years..	dbadvn	Read Full Thread Reply
04/4/2018 12:08	Good to hear that Nerd. This event will be like manna from heaven :-)	thornyone	Read Full Thread Reply
04/4/2018 11:04	in response to your No. 1385 thorny, the CFDA now take no longer than the U.S. FDA in terms of granting the NDA approval. They also have a fast track process, which we are using. The Company fully espects approval in the next few months.	nerdofsteel	Read Full Thread Reply
04/4/2018 10:16	Interesting chart analysis haydock and fairly convincing. So he's saying a possible brief recovery to around £48 then a resumption of the downtrend to around £33 before a possible slow recovery. As you know technical analysis doesn't always play out and can be overshadowed by transformational news events. For example the anticipated Chinese government decision to approve a licence to market. 5 NASDAQ analysts apparently don't agree with the chart analysis either. Time will tell.	reptile3	Read Full Thread Reply
04/4/2018 09:06	https://uk.advfn.com/cmn/fbb/thread.php3?id=40296935 Bikwik has kindly done extensive charting on HCM. Suggest well worth a look.	haydock	Read Full Thread Reply

Chat Pages: 60 59 58 57 56 55 54 53 52 51 50 49 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.